TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.

Authors

Yelena Janjigian

Yelena Y. Janjigian

Memorial Sloan Kettering Cancer Center, New York, NY

Yelena Y. Janjigian , Ana Oaknin , Joshua Michael Lang , Kristen Keon Ciombor , Isabelle Laure Ray-Coquard , Amit M. Oza , Kan Yonemori , Rui-Hua Xu , Jimmy Zhao , Srikanth Gajavelli , Justyna Filant , Tina Hovey , Funda Meric-Bernstam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT05489211

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS3153)

DOI

10.1200/JCO.2023.41.16_suppl.TPS3153

Abstract #

TPS3153

Poster Bd #

351a

Abstract Disclosures